3,4-二胺基苄氧基三氟化物 | 368-71-8

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二胺基苄氧基三氟化物
• 中文别名: 3,4-二氨基三氟甲苯；4-三氟甲基-1,2-苯二胺；3,4-二胺基苄基三氟化物；4-三氟甲基邻苯二胺
• 英文名称: 4-(trifluoromethyl)-1,2-phenylenediamine
• 英文别名: 4-trifluoromethyl-1,2-benzenediamine；4-(trifluoromethyl)benzene-1,2-diamine；3,4-diaminobenzotrifluoride；4-trifluoromethyl-o-phenylenediamine
• CAS: 368-71-8
• 化学式: C₇H₇F₃N₂
• mdl: MFCD00042456
• 分子量: 176.141
• InChiKey: RQWJHUJJBYMJMN-UHFFFAOYSA-N

物化性质

• 熔点：
  56-58 °C
• 沸点：
  253℃
• 密度：
  1.381
• 闪点：
  111℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT-HARMFUL
• 危险等级：
  6.1
• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2921590090
• 安全说明：
  S26,S36/37/39
• WGK Germany：
  3
• 储存条件：
  | 室温 |

SDS

Name:	4-(Trifluoromethyl)-1 2-phenylenediamine Material Safety Data Sheet
Synonym:	None Known
CAS:	368-71-8

Section 1 - Chemical Product MSDS Name:4-(Trifluoromethyl)-1 2-phenylenediamine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
368-71-8	4-(Trifluoromethyl)-1,2-phenylenediami	99	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
The toxicological properties of this substance have not been fully investigated.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 368-71-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: grey - brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 58 - 60 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7F3N2
Molecular Weight: 176.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen fluoride gas, nitric acid.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 368-71-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Trifluoromethyl)-1,2-phenylenediamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 368-71-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 368-71-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 368-71-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于制药和农药中间体生产。

反应信息

• 作为反应物：
  描述：

  3,4-二胺基苄氧基三氟化物 在 盐酸 、 selenium(IV) oxide 、 硫酸 、 氢碘酸 、 硝酸 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 3-硝基-5-(三氟甲基)苯-1,2-二胺
  参考文献：
  名称：

  取代的1,4-二氢喹喔啉-2,3-二酮的合成与构效关系：N-甲基-D-天冬氨酸（NMDA）受体甘氨酸位点和非NMDA谷氨酸受体的拮抗剂。

  摘要：

  合成了一系列的单，二，三和四取代的1,4-二氢喹喔啉-2,3-二酮（QXs），并在N-甲基-D-天冬氨酸（NMDA）/甘氨酸位点和α位作为拮抗剂进行了评估-氨基-3-羟基-5-甲基异恶唑-4-丙酸优先的非NMDA受体。通过电测定在表达大鼠全脑poly（A）+ RNA的非洲爪蟾卵母细胞中测量拮抗剂的效力。三取代QX 17a（ACEA 1021），17b（ACEA 1031），24a和27，在5位含硝基，在6和7位含卤素，在甘氨酸上显示出高效价（Kb约为6-8 nM）位点，对非NMDA受体的药效中等（Kb = 0.9-1.5 microM），与非NMDA受体相比，甘氨酸位点拮抗作用的选择性最高（120-250倍）。四取代的QX 17d e是比相应的三取代QX弱100倍的弱甘氨酸位点拮抗剂，在8位上F作为取代基比Cl具有更好的耐受性。与三取代类似物相比，二取代和单取代的QX显示出越来越弱的拮抗作

  DOI：

  10.1021/jm00022a003
• 作为产物：
  描述：

  3-氨基-4-硝基三氟甲苯 在 氢气 作用下， 以 乙醇 为溶剂， 生成 3,4-二胺基苄氧基三氟化物
  参考文献：
  名称：

  苯并[ d ]咪唑衍生物的合成，血管舒张活性和降压作用

  摘要：

  使用短合成路线合成了一系列在5位被–CF 3或–NO 2取代的1 P苯并本的1 H-苯并[ d ]咪唑类似物。所有硝基衍生物均有效，并表现出浓度依赖性和部分内皮依赖性血管舒张作用，EC 50 s <5μM。2-甲氧基-4- [5-硝基-1 H-苯并[ d ]咪唑-2-基]苯酚（化合物13）是该系列中最有效的衍生物，其EC 50值为1.81μM，E max完整的主动脉环中离体舒张反应的抗氧化活性为91.7％，与Pimobendan相比，活性提高了2.5倍。密切相关的5-CF 3类似物（化合物8）的效价比13低19倍。使用自发性高血压大鼠（SHR）在25、50和100 mg kg -1的剂量下评估了化合物13的抗高血压活性，显示出统计学上显着的剂量依赖性效应。

  DOI：

  10.1016/j.bmc.2010.04.027
• 作为试剂：
  描述：

  3,4-二胺基苄氧基三氟化物 、 在 3,4-二胺基苄氧基三氟化物 作用下， 生成 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one
  参考文献：
  名称：

  FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

  摘要：

  提供了某些融合三环化合物及其盐，它们的组成物和使用方法。

  公开号：

  US20150045355A1

文献信息

• Iridium-catalyzed direct C–H amidation of anilines with sulfonyl azides: easy access to 1,2-diaminobenzenes
  作者：Lianhui Wang、Zi Yang、Mengqi Yang、Rongyi Zhang、Changsheng Kuai、Xiuling Cui

  DOI：10.1039/c7ob01899a

  日期：——

  An Ir(III)-catalyzed regioselective C–H amidation of anilines with sulfonyl azides is described. The developed protocol has good compatibility with diverse functional groups, efficiently providing the monoamidated products with good to excellent yields under mild reaction conditions. Furthermore, the 2-pyrimidyl and sulfonyl moieties in the amidated products can readily be removed, offering the synthetically

  描述了一种Ir（III）催化的苯胺与磺酰叠氮化物的区域选择性CH酰胺化反应。所开发的方案与各种官能团具有良好的相容性，可在温和的反应条件下有效地为单酰胺化产物提供良好或优异的收率。此外，可以容易地除去酰胺化产物中的2-嘧啶基和磺酰基部分，从而提供了合成上有用的1，2-二氨基苯支架。
• [EN] IMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012015693A1

  公开（公告）日：2012-02-02

  Described herein are compounds of formula (I) :The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述了化合物的结构式(I)：结构式I的化合物作为DGAT1抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。
• THE CONDENSATION OF PHOSPHONOTHIOIC AND PHOSPHONIC DICHLORIDES WITH <i>o</i>-DIAMINES
  作者：Ralph L. Dannley、Arturs Grava

  DOI：10.1139/v65-469

  日期：1965.12.1

  dichlorides, and phenylenediamines containing electron-donating substituents are more reactive than those containing electron-withdrawing substituents. The diazaphosphole 2-oxides undergo hydrolysis or alcoholysis of only one of the amide groups under mild conditions. The 2-sulfides are much more resistant to hydrolysis than the 2-oxides. The 2-sulfides are converted to the N-methyl derivatives by dimethyl

  已经制备了一系列 2,3-二氢-1H-1,3,2-苯并二氮杂磷 2-硫化物和 2-氧化物，最常见的方法是在回流惰性溶剂中将二胺与膦硫代或膦酰二氯化物缩合。硫代膦酰二氯化物比相应的膦酰二氯反应更慢，含有给电子取代基的苯二胺比含有吸电子取代基的苯二胺反应性更强。二氮杂磷酰 2-氧化物在温和条件下仅对其中一个酰胺基进行水解或醇解。2-硫化物比2-氧化物更耐水解。2-硫化物被硫酸二甲酯和碱转化为N-甲基衍生物。2-氧化物在这些条件下水解。
• Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives
  作者：Michele Tonelli、Matteo Simone、Bruno Tasso、Federica Novelli、Vito Boido、Fabio Sparatore、Giuseppe Paglietti、Sabrina Pricl、Gabriele Giliberti、Sylvain Blois、Cristina Ibba、Giuseppina Sanna、Roberta Loddo、Paolo La Colla

  DOI：10.1016/j.bmc.2010.02.037

  日期：2010.4

  Seventy-six 2-phenylbenzimidazole derivatives were synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against a panel of 10 RNA and DNA viruses. The most commonly affected viruses were, in decreasing order, CVB-2, BVDV, Sb-1, HSV-1, and YFV, while HIV-1 and VSV were not affected, and RSV, VV and Reo-1 were only susceptible to a few compounds. Thirty-nine compounds

  合成了76种2-苯基苯并咪唑衍生物，并在基于细胞的测定中评估了其对一组10种RNA和DNA病毒的细胞毒性和抗病毒活性。受影响最严重的病毒以降序排列，分别是CVB-2，BVDV，Sb-1，HSV-1和YFV，而HIV-1和VSV不受影响，RSV，VV和Reo-1仅易感一些化合物。39种化合物表现出 对至少一种病毒的高活性（EC 50 = 0.1–10μM），其中四种对VV（24，EC 50  = 0.1μM）和BVDV（50，具有EC 50的51和53 分别为1.5、0.8和1.0μM）。最后的化合物在低微摩尔浓度下抑制BVDV和HCV的NS5B RdRp，后者与前者具有结构相似性。所考虑的化合物代表了针对痘病毒，瘟病毒甚至HCV（它们是重要的人类和兽医病原体）的抗病毒剂开发的诱人线索。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。

表征谱图